AU2020374150B2 - ALK inhibitors for treatment of ALK-negative cancer and plasma cell-mediated diseases - Google Patents

ALK inhibitors for treatment of ALK-negative cancer and plasma cell-mediated diseases

Info

Publication number
AU2020374150B2
AU2020374150B2 AU2020374150A AU2020374150A AU2020374150B2 AU 2020374150 B2 AU2020374150 B2 AU 2020374150B2 AU 2020374150 A AU2020374150 A AU 2020374150A AU 2020374150 A AU2020374150 A AU 2020374150A AU 2020374150 B2 AU2020374150 B2 AU 2020374150B2
Authority
AU
Australia
Prior art keywords
alk
crizotinib
cells
cancer
ltk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020374150A
Other languages
English (en)
Other versions
AU2020374150A1 (en
Inventor
Andrej BESSE
Lenka BESSE
Christoph Driessen
Hesso Farhan
Mariaserena GILIBERTO
Fredrik HELLEM SCHJESVOLD
Ludvig Munthe
Sigrid SKÅNLAND
Kjetil Tasken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitetet i Oslo
Original Assignee
I Oslo, University of
Universitetet i Oslo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Oslo, University of, Universitetet i Oslo filed Critical I Oslo, University of
Publication of AU2020374150A1 publication Critical patent/AU2020374150A1/en
Application granted granted Critical
Publication of AU2020374150B2 publication Critical patent/AU2020374150B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2020374150A 2019-10-28 2020-03-12 ALK inhibitors for treatment of ALK-negative cancer and plasma cell-mediated diseases Active AU2020374150B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201915618A GB201915618D0 (en) 2019-10-28 2019-10-28 ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
GB1915618.1 2019-10-28
PCT/EP2020/056698 WO2021083555A1 (en) 2019-10-28 2020-03-12 Alk inhibitors for treatment of alk-negative cancer and plasma cell-mediated diseases

Publications (2)

Publication Number Publication Date
AU2020374150A1 AU2020374150A1 (en) 2022-06-09
AU2020374150B2 true AU2020374150B2 (en) 2025-12-18

Family

ID=68768829

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020374150A Active AU2020374150B2 (en) 2019-10-28 2020-03-12 ALK inhibitors for treatment of ALK-negative cancer and plasma cell-mediated diseases

Country Status (9)

Country Link
US (1) US12465607B2 (https=)
EP (1) EP4051288A1 (https=)
JP (1) JP7629228B2 (https=)
KR (1) KR102946955B1 (https=)
CN (1) CN114901289A (https=)
AU (1) AU2020374150B2 (https=)
CA (1) CA3159339A1 (https=)
GB (1) GB201915618D0 (https=)
WO (1) WO2021083555A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230091284A (ko) * 2021-12-16 2023-06-23 부산대학교 산학협력단 Surf4 억제제를 포함하는 혈액암의 예방 또는 치료용 약학적 조성물
WO2024017334A1 (zh) * 2022-07-22 2024-01-25 贝达药业股份有限公司 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒
CN115993453B (zh) * 2022-07-22 2025-03-25 四川大学 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒
WO2024059525A2 (en) * 2022-09-12 2024-03-21 Endotarget, Inc. Compounds and methods for the targeted degradation of anaplastic lymphoma kinase and ros1 kinase
KR20250160958A (ko) * 2023-03-22 2025-11-14 어센테지 파마 (쑤저우) 컴퍼니 리미티드 약학적 조합 및 이의 응용
CN119700981A (zh) * 2024-12-24 2025-03-28 中南大学湘雅二医院 Alk/ltk抑制剂在制备治疗和/或预防慢性淋巴细胞白血病的产品中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2017058780A1 (en) * 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
WO2019141235A1 (zh) * 2018-01-20 2019-07-25 中国科学院上海药物研究所 治疗肝癌的药物组合和方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017405B9 (ru) 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
AU2009233963B2 (en) 2008-04-07 2011-10-06 Irm Llc Compounds and compositions as kinase inhibitors
US8904383B2 (en) 2008-04-10 2014-12-02 Hewlett-Packard Development Company, L.P. Virtual machine migration according to environmental data
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
BR112013015000A2 (pt) 2010-12-17 2016-08-09 Novartis Ag formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina
EP2916841A1 (en) 2012-11-07 2015-09-16 Novartis AG Combination therapy
US10117872B2 (en) 2014-03-28 2018-11-06 Università Degli Studi Di Genova Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
CN105294649B (zh) 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
US10695426B2 (en) * 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
KR20170060042A (ko) * 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2016098042A1 (en) 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
JPWO2019039390A1 (ja) 2017-08-25 2020-07-30 国立大学法人東海国立大学機構 若年性骨髄単球性白血病治療薬
WO2019113345A1 (en) 2017-12-06 2019-06-13 Spyro Mousses Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2017058780A1 (en) * 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
WO2019141235A1 (zh) * 2018-01-20 2019-07-25 中国科学院上海药物研究所 治疗肝癌的药物组合和方法

Also Published As

Publication number Publication date
KR102946955B1 (ko) 2026-04-02
CA3159339A1 (en) 2021-05-06
JP2022554258A (ja) 2022-12-28
GB201915618D0 (en) 2019-12-11
WO2021083555A1 (en) 2021-05-06
EP4051288A1 (en) 2022-09-07
CN114901289A (zh) 2022-08-12
US20220401444A1 (en) 2022-12-22
JP7629228B2 (ja) 2025-02-13
US12465607B2 (en) 2025-11-11
KR20220098158A (ko) 2022-07-11
AU2020374150A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
AU2020374150B2 (en) ALK inhibitors for treatment of ALK-negative cancer and plasma cell-mediated diseases
Bhansali et al. DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3
O'Hare et al. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia
Liang et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex
US10017767B2 (en) Targets in multiple myeloma and other disorders
US10130590B2 (en) Methods of treating cancer with atovaquone-related compounds
Tao et al. Caffeine promotes the expression of telomerase reverse transcriptase to regulate cellular senescence and aging
US11696924B2 (en) Combination therapy using PDK1 and PI3K inhibitors
Hung et al. SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A
EP3661924A1 (en) Compounds, compositionals, and methods for treating t-cell acute lymphoblastic leukemia
JP2007526882A (ja) リンパ球性白血病を治療するためのロスコビチンの使用
Kannan et al. Antileukemia effects of notch-mediated inhibition of oncogenic PLK1 in B-cell acute lymphoblastic leukemia
KR20150131155A (ko) 종양 약역학적 반응의 바이오마커
Martelli et al. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy
US20210252009A1 (en) Composition comprising flt3 inhibitor as effective ingredient for inhibiting drug resistance in chronic myelogenous leukemia
EP2979708A1 (en) Composition for treatment or metastasis suppression of cancers which includes p34 expression inhibitor or activity inhibitor as active ingredient
WO2015134603A2 (en) Methods for treating cancer
US20090239884A1 (en) Methods of Treating Inflammation
EP3125896A2 (en) EXPRESSION LEVELS OF BCL-xL, BCL2, BCL-w, AND BAD AND CANCER THERAPIES
Wodi Targeting the Splice Factor Kinases SRPK1 and CLK1 in Leukaemia
Roleder et al. Cyclin-dependent kinase-9 and oxidative phosphorylation inhibition overcome ibrutinib resistance in mantle cell lymphoma
KR20250173492A (ko) 신경교종의 치료용 의약 조성물
Tandon S6K1 mediates oncogenic glycolysis in Pten deficient leukemia
Agarwal et al. G-CSF promotes neuroblastoma tumorigenicity and metastasis via STAT3-dependent
Dixit Interferon-γ modulates intestinal P-glycoprotein: Molecular mechanism and clinical implications

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)